{"id":"W3201548322","doi":"10.1093/noajnl/vdab112.036","title":"SYST-08. A phase II trial of concurrent Sunitinib, Temozolomide and Radiation Therapy followed by adjuvant Temozolomide for newly diagnosed Glioblastoma patients with an unmethylated MGMT gene promoter (A01-M121-11A, McG1132)","year":2021,"lang":"en","type":"article","venue":"Neuro-Oncology Advances","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; University of Calgary; McGill University Health Centre","funders":"","keywords":"Temozolomide; Medicine; Sunitinib; Internal medicine; Oncology; Hazard ratio; Adjuvant; Phases of clinical research; Progression-free survival; Radiation therapy; Clinical trial; Chemotherapy; Cancer; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001448937,0.001046745,0.001430327,0.0005645547,0.0002471165,0.000723569,0.0006522012,0.00101416,0.003849662],"category_scores_gemma":[0.0005850445,0.0005293876,0.001421174,0.0003466584,0.0007332437,0.0005453666,0.0002773799,0.00175491,0.0007221114],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000919089,"about_ca_system_score_gemma":0.001694078,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001072793,"about_ca_topic_score_gemma":0.005257183,"domain_scores_codex":[0.9995852,0.0002245581,0.00002944202,0.00005484492,0.0000278326,0.00007803537],"domain_scores_gemma":[0.9996222,0.00006124463,0.00008074976,0.00002009214,0.00002489694,0.0001907222],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8768536,0.02151385,0.007902455,0.001393434,0.001906478,0.0001580908,0.0001457583,0.001600452,0.0283442,0.0005312036,0.00393456,0.05571585],"study_design_scores_gemma":[0.7291072,0.2527845,0.01025684,0.00005551696,0.001105291,0.0001639234,0.00003331937,0.000970084,0.002831426,0.0001722303,0.002496077,0.00002359842],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9897773,0.002805913,0.000416633,0.0004659756,0.0001967753,0.002231461,0.002022665,0.0001374493,0.001945726],"genre_scores_gemma":[0.9839644,0.001730536,0.002110589,0.0007926234,0.0001582267,0.003166108,0.0043445,0.00001938383,0.003713536],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003849662,"threshold_uncertainty_score":0.01287836,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01452681636841457,"score_gpt":0.311337398229012,"score_spread":0.2968105818605974,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}